The MVPE-CC consortium held its Investigators meeting from 2-5 September 2024 in Accra, Ghana. The meeting brought together representatives from seven consortium institutions including Kintampo Health Research Centre of the Research and Development Division of Ghana Health Service (Coordinating Institution), European Vaccine Initiative, London School of Hygiene and Tropical Medicine, African Research Collaboration for Health Limited, Kenya Medical Research Institute, Kamuzu University of Health Sciences, PATH and collaborating partner World Health Organization (WHO).

The MVPE-CC consortium aims to evaluate the incremental benefit of the 4th RTS,S/AS01 (RTS,S) malaria vaccine dose, as well as the magnitude of rebound effects, if observed in children who receive only the primary series of 3 doses. Findings from this study will inform potential future changes to WHO recommendations for malaria vaccines and may have implications for vaccine cost, cost effectiveness, and schedule adherence.

With data analysis and WHO evidence review planned in quarter four of 2024, MVPE-CC investigators’ meeting was scheduled to discuss preliminary data analysis, key study outputs, results dissemination timelines and identify key policy questions for WHO’s advisory groups (MVIP DSMB and SAGE-MPAG Working Group). At end of the 4-day meeting, the team finalized timelines for sharing of preliminary and final results, mapped out platforms for dissemination of study findings at country and global levels, determined policy questions for WHO advisory groups and reviewed financial budgets for successful closure of the study.